GSK Glaxosmithkline plc - ADR

$GSK What is the cure for dementia worth these days? DOUBLE WOW, might make $MRNA look like child's play. And, I love Moderna. Fact check my posts from like October 2025 to August 2026. Looking for some place for Moderna money. This is one place. $MRK

31 days out on $GSK and the lung cancer file is the one I keep circling back to Nov 27 PDUFA for neladalkib, a brain penetrant ALK drug GSK picked up in the Nuvalent deal, for ALK positive lung cancer after earlier ALK drugs stop working ALKOVE 1 gave it real numbers. 31% response across pretreated patients, 46% in folks who never had lorlatinib, 68% in the G1202R resistance group the brain data is the part that matters most imo. 32% intracranial response in patients with measurable brain lesions, built TRK sparing so the nasty CNS side effects stay rare Priority Review plus Breakthrough and Orphan tags, and first line data was even louder at 86% response, though that is a later fight a big pharma name with a small biotech catalyst tucked inside it. those are my favorite kind of setups into a date

$GSK $IONS Official PR dropped at the AH close Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)

$GSK Follow-up: UK drugmaker GSK (early Ris-Rez lung data, 18 Oct) won US accelerated approval for Jemperli in MSI-H/dMMR rectal cancer; on the trial's primary endpoint, independent review, 47% (54/116) had a 12-month complete response vs 68% by investigators. Niche vs a ~$106.86B market value ($49.525, 13:16 ET Oct 19, 2026): the biomarker is in about 5-10% of rectal cancers. No recurrence reported among responders after over two years' median follow-up, and 38 more short of 12 months already show complete response. Full data at ESMO this month.

Quiet one I keep circling, $GSK imo 23 days out, Nov 27 PDUFA for neladalkib in ALK positive lung cancer that already failed a prior ALK drug Priority Review in hand, Breakthrough tag too, built on ALKOVE 1 and designed to get into the brain where older ALK drugs struggle GSK paid 10.6 billion for Nuvalent to own it, and the stock is near 51 today. a date with a real launch behind it, not just a headline

$GSK Is GSK's 2% Q3 vaccine slide, with Shingrix down 5%, a bigger problem than its 15% specialty growth? 🏢 UK drugmaker GSK won US approval for hepatitis B drug Hibsago (6-K, 20 Oct 2026), and its Q3 2026 sales have now risen 5% at constant currency to £8.9bn, with the company valued at about $106.15B at $49.195 a US receipt (11:01 ET, Oct 28, 2026) 📉 Vaccines fell 2% to £2.6bn in the quarter because Shingrix dropped 5% to £780m on lower sales outside the US and Europe, mainly China, and RSV vaccine Arexvy fell 24% to £195m on lower demand 📈 Against that, Specialty Medicines grew 15% to £3.9bn, with Oncology up 23%, vaccines are still up 3% for the year to date, and GSK still expects full-year vaccine sales to be broadly stable or up by a low single-digit percentage 📅 Next: ADRs go ex-dividend on 13 November 2026, and the 17p dividend is paid on 7 January 2027 Source: SEC 6-K, Oct 28 + SEC 6-K, Oct 21

$GSK | GSK Q3 2026 Earnings - Revenue: £8.89B (est £8.86B) - Adj EPS: 54.6p (est 50.3p) - Shingrix Revenue: £780M (est £855.9M) - Sees 2026 Core EPS: +7% To +9%, At Lower Half Of Range - 2026 Guidance Reaffirmed - 2026 Core EPS Impacted By Interest Charges Of £700M-£750M

$GSK reports earnings tomorrow before the open. I’m bullish heading into the report: GSK has beaten EPS estimates in 8 of its last 8 reports, according to Stock Meadow. What are you watching for?

Hansoh Pharmaceutical and GSK reported that their experimental osteosarcoma treatment, ris-rez, significantly prolonged progression-free survival compared with chemotherapy in a late-stage clinical trial conducted in China. Patients receiving ris-rez achieved median progression-free survival of 5.5 months, versus just 1.4 months for those receiving chemotherapy, highlighting the drug’s potential for patients with limited treatment options. The trial enrolled 122 patients aged 12 and older with relapsed or refractory osteosarcoma who had previously received more than two lines of treatment. Ris-rez is a targeted cancer therapy designed to deliver cytotoxic drugs directly to tumors while largely limiting damage to healthy tissue. According to trial leader Lu Xie of Peking University People’s Hospital, the treatment reduced the risk of disease progression or death by 67% compared with chemotherapy. $GSK

quiet clock on $GSK imo Nov 27 PDUFA, 36 days out, neladalkib in ALK positive lung cancer after a TKI Priority Review, Breakthrough and Orphan in hand, built to reach the brain and cover resistance mutations the older drugs miss trading 50.84 today, up 1.6 percent off a 50.02 close, and it came over in a 10.6 billion dollar deal for a reason ngl

https://stocktwits.com/news-articles/markets/equity/gsk-inovio-agios-sun-pharma-fda-decision-calendar-october/cZx8jI5RBML $GSK Inovio investors rallied shares to $14.74 on 3/31/2024 and the same value is likely to prevail on 10/30/26, reduced for shares issued, 4:1, but still 260% gains likely.

$GSK Follow-up: UK drugmaker GSK, a day after its 19 Oct 6-K on Jemperli's US rectal-cancer approval, won US approval for hepatitis B drug Hibsago, with a boxed warning for liver flares and sudden, possibly life-threatening low platelets. Label: adults without cirrhosis, on NrtI 6+ months, HBsAg ≤3,000 IU/mL; weekly platelet checks. GSK value ~$109.25B ($50.63/receipt, 20 Oct 2026 close at 16:00 ET). In return: a six-month course gave 19% functional cure (233/1,220) vs 0/614 on placebo. Other markets' decisions due in coming months.

$GSK GSK Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer "today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway."

A rectal cancer treatment with no surgery, radiation or chemo just got FDA approval. $GSK Jemperli (MSI-H/dMMR, stage II/III): 71% of 154 patients needed no other treatment. Approved about 4 months early. Full data at ESMO Sun Oct 25. It's on the calendar 📅

$GSK Wolfe started coverage Friday with an Outperform and a 70 target, about 50% above where the shares closed. Consensus is still a Hold at 55.33, so Wolfe is roughly 27% above the street on a name down 20% over the last six months. Initiating that high on a beaten-up pharma stock is a pretty loud call.